PartnershipApr 30, 2026, 04:19 PM
EVFM Signs Exclusive Distributorship for SOLOSEC in Sub-Saharan Africa
AI Summary
Evofem Biosciences, Inc. announced an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC, effective April 24, 2026. This five-year agreement grants Clovis Davis the rights to commercialize SOLOSEC (secnidazole) 2g oral granules in Sub-Saharan Africa. Clovis Davis will manage the distribution, promotion, marketing, and sales, utilizing Evofem's U.S. FDA-approved registration dossier for local regulatory approvals. SOLOSEC is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis, conditions with significant prevalence in the region.
Key Highlights
- Evofem Biosciences entered an exclusive distributorship agreement with Clovis Davis Pharmaceuticals on April 24, 2026.
- The agreement covers commercialization of SOLOSEC (secnidazole) 2g oral granules in Sub-Saharan Africa for five years.
- Clovis Davis will lead distribution, promotion, marketing, and sales of SOLOSEC in the Territory.
- Local regulatory filings for SOLOSEC approval will be based on Evofem's U.S. FDA-approved dossier.
- SOLOSEC is an FDA-approved single-dose oral treatment for bacterial vaginosis (BV) and trichomoniasis (Trich).
- BV is estimated to affect 25% of women in Sub-Saharan Africa.
- Approximately 10.9 million women in Ethiopia alone may be eligible for SOLOSEC treatment.
- WHO estimated 156 million new cases of Trichomoniasis globally in 2020, with one-third in the African Region.
Price Impact
More from EVFM